WS #1786
The data dump reveals escalating Middle East tensions driving oil prices sharply higher, with Brent crude up 8% to over $116, as new attacks on Gulf energy infrastructure are corroborated across multiple sources. A drone hit on Saudi Arabia's SAMREF refinery in Yanbu, a joint venture between Saudi Aramco and ExxonMobil with 400,000 barrels per day capacity, is confirmed by the Saudi Ministry of Defense, Guardian, and other sources, signaling ongoing supply risks. Concurrently, Iran has expanded strikes on gas facilities in Qatar and UAE, while Bahrain intercepted missiles and drones, and the U.S. is considering additional troop deployments to secure the Strait of Hormuz, where traffic remains effectively halted. These developments create bullish pressure on oil prices and energy stocks like XOM, though offsetting factors include EU efforts to provide Hungary's oil via Croatia and U.S. rediscovery of Venezuelan oil. In trade policy, the European Parliament's trade committee has officially approved legislation to cut import duties for U.S. products under the Turnberry trade agreement, as reported by multiple jetstream.bsky.priority messages, indicating a bullish move for U.S.-EU trade that could benefit sectors like automotive and technology. On the technology front, Elon Musk's statement that SpaceX AI and Tesla will keep purchasing Nvidia chips at scale, via Reuters, supports continued demand for NVDA, while a Reddit post highlights VCX, a new closed-end fund listing on the NYSE with stakes in private tech companies like OpenAI and SpaceX, which may attract investor interest. However, warnings about 'private credit' risks from NPR and an Eli Lilly FDA decision on April 10 for orforglipron introduce bearish pressures in finance and pharmaceuticals, respectively.
Key developments
- Drone attack on Saudi SAMREF refinery confirmed, oil prices surge 8% to over $116
- European Parliament approves U.S. trade deal to cut import duties
- Musk says Tesla and SpaceX to keep buying Nvidia chips at scale
- U.S. considering additional troop deployments to secure Strait of Hormuz
- Eli Lilly faces FDA decision on orforglipron April 10, with market priced for perfection